Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.39 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633725 | 0.82 | CACNA2D1 (0.43) | OPRD1CACNA2D1CACNA1BCACNB1SLC6A2 | |
| SCHEMBL5634353 | 0.70 | SLC6A2 (0.41) | OPRD1CACNA2D1CACNA1BCACNB1SLC6A2 | |
| SCHEMBL5633714 | 0.70 | LMNA (0.45) | OPRD1CACNA2D1CACNA1BCACNB1PKM | |
| SCHEMBL5633551 | 0.70 | SLC6A2 (0.40) | OPRD1CACNA2D1CACNA1BCACNB1SLC6A2 | |
| SCHEMBL13920771 | 0.69 | SLC6A4 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL5633971 | 0.69 | SOS1 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5633511 | 0.67 | SLC6A2 (0.40) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5080882 | 0.67 | SMYD3 (0.50) | OPRD1MAPTPKMSMYD3 | |
| SCHEMBL5634378 | 0.65 | SLC6A2 (0.46) | CACNA2D1CACNA1BCACNB1SLC6A2SLC6A4 | |
| SCHEMBL5634881 | 0.65 | SLC6A2 (0.42) | OPRD1CACNA2D1CACNA1BCACNB1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244758-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-07-17 | — | — | US | claimed |
| US-20050014748-A1 | N-type calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2005-01-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014748-A1 | N-type calcium channel blockers | CACNA1B, CACNA1C, CACNA1I | OPRD1 212/4885CACNA2D1 30/4885CACNA1B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.